Compared with non-CLBC, patients with less aggressive characteristics such as lower histologic grade, smaller tumor size, none or limited lymph node metastasis, positive hormone receptor status, or negative HER-2 in CLBC cohorts were more likely to receive mastectomy, instead of BCS. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.